Protalix BioTherapeutics reported strong year-to-date revenue growth of 24%, though third-quarter revenues showed a slight decline of 1% compared to the previous year, reflecting ongoing inventory management by key partners.

• Total revenues for the first nine months of 2025 reached $46.4 million, marking a 24% year-over-year increase.
• Third-quarter revenue was $17.9 million, down 1% year-over-year due to variable inventory control by partners.
• The company is advancing its PRX-115 candidate for the treatment of uncontrolled gout, having filed for a Phase 2 clinical trial.
• Research and development expenses surged by 58% for the first nine months, emphasizing continued investment in pipeline projects.
• Protalix maintains a strong cash position and positive net income, supporting its strategic focus on commercial success and innovation.